FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia.

Humans fms-Like Tyrosine Kinase 3 / genetics Neoplasm, Residual / diagnosis Leukemia, Myeloid, Acute / genetics Polymerase Chain Reaction / methods Mutation Female Male Middle Aged Aged Adult High-Throughput Nucleotide Sequencing / methods
FMS-like tyrosine kinase acute myeloid leukemia clonal evolution measurable residual disease precision oncology treatment monitoring

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
26 May 2024
Historique:
received: 28 03 2024
revised: 18 05 2024
accepted: 21 05 2024
medline: 19 6 2024
pubmed: 19 6 2024
entrez: 19 6 2024
Statut: epublish

Résumé

The tyrosine kinase domain of the FMS-Like tyrosine kinase 3 (

Identifiants

DOI: 10.3390/ijms25115771 PMID: 38891959
pubmed: 38891959
pii: ijms25115771
doi: 10.3390/ijms25115771
pii:
doi:

Substances chimiques

fms-Like Tyrosine Kinase 3 EC 2.7.10.1
FLT3 protein, human EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Eric Wenlong Li (EW)

Institute of Hematology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Molecular Hematology Laboratory, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia.
ORCID: 0000-0002-6688-8511

Ngoc Yen Kim Tran (NYK)

Molecular Hematology Laboratory, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.

Derek McCulloch (D)

Institute of Hematology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Molecular Hematology Laboratory, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia.

Michael Krigstein (M)

Department of Hematology, St Vincent's Hospital, Sydney, NSW 2010, Australia.
ORCID: 0000-0002-6964-9591

Alberto Catalano (A)

Molecular Hematology Laboratory, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.

Jad Othman (J)

Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia.
Department of Hematology, Royal North Shore Hospital, Sydney, NSW 2065, Australia.

Edward Abadir (E)

Institute of Hematology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia.

Cheryl Smith (C)

Molecular Hematology Laboratory, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.

Harry Iland (H)

Institute of Hematology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Molecular Hematology Laboratory, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia.

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › FLT3-TKD Measurable Residual Disease Detection...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Tyrosine kinase-3 de type fms › FLT3-TKD Measurable Residual Disease Detection...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Maladie résiduelle › FLT3-TKD Measurable Residual Disease Detection...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › FLT3-TKD Measurable Residual Disease Detection...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Techniques d'amplification d'acides nucléiques › Réaction de polymérisation en chaîne › FLT3-TKD Measurable Residual Disease Detection...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › FLT3-TKD Measurable Residual Disease Detection...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › FLT3-TKD Measurable Residual Disease Detection...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › FLT3-TKD Measurable Residual Disease Detection...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › FLT3-TKD Measurable Residual Disease Detection...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Séquençage nucléotidique à haut débit › FLT3-TKD Measurable Residual Disease Detection...